Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504
Equillium dosed the first subject in a Phase 1 trial of EQ504, an oral colon-targeted AhR modulator for inflammatory diseases, with topline proof-of-mechanism data expected in Q2 2027. The milestone triggered the closing of an additional $20 million tranche under its August 2025 private placement — 14,957,260 shares at $0.57 and 20,130,457 pre-funded warrants at $0.5669 — bringing total placement proceeds to roughly $50 million. With the new capital, cash runway extends into 2029, and a placebo-controlled Phase 2 proof-of-concept study in ulcerative colitis is planned for the second half of 2027.
Key figures
- Drug Name
- EQ504
- Deal Value Usd
- 20000000
- Phase Of Trial
- Phase 1
- Offering Price
- 0.57
- Cash runway
- into 2029
- Subjects enrolled
- 70
- Prefunded warrants
- 20130457
- Topline data timing
- Q2 2027
- Prefunded warrant price
- 0.5669
- Placement tranche shares
- 14957260
- Total placement proceeds
- $50 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.